Biological evaluation of both enantiomers of fluoro-thalidomide using human myeloma cell line H929 and others. [PDF]
PLoS ONE, 2017 Over the last few years, thalidomide has become one of the most important anti-tumour drugs for the treatment of relapsed-refractory multiple myeloma. However, besides its undesirable teratogenic side effect, its configurational instability critically ...
Etsuko Tokunaga +5 more
doaj +1 more source
Cells, 2023 Allergy is a chronic inflammatory disease, and its incidence has increased worldwide in recent years. Thalidomide, which was initially used as an anti-emetic drug but was withdrawn due to its teratogenic effects, is now used to treat blood cancers ...
Hyeun-Wook Chang +2 more
doaj +1 more source
Thalidomide attenuates nitric oxide mediated angiogenesis by blocking migration of endothelial cells
BMC Cell Biology, 2006 Background Thalidomide is an immunomodulatory agent, which arrests angiogenesis. The mechanism of anti-angiogenic activity of thalidomide is not fully understood.
Indhumathy M +5 more
doaj +1 more source
Thalidomide inhibits alternative activation of macrophages in vivo and in vitro: a potential mechanism of anti-asthmatic effect of thalidomide. [PDF]
PLoS ONE, 2015 Thalidomide is known to have anti-inflammatory and immunomodulatory actions. However, the effect and the anti-asthmatic mechanism of thalidomide in the pathogenesis of asthmatic airways are not fully understood.This study is designed to determine the ...
Hyun Seung Lee +9 more
doaj +1 more source
Arterial dysgenesis and limb defects : Clinical and experimental examples [PDF]
, 2017 Acknowledgements This article is dedicated to Dr David S. Packard Jr. With thanks to Dr John DeSesso, Dr Lewis B. Holmes, Dr Mark Levinsohn, Dr David S.
Hootnick, David R., Vargesson, Neil
core +1 more source
Journal of Hematology & Oncology, 2010 Background Thalidomide based regimen is an effective and well tolerated therapy in multiple myeloma (MM) patients, however, there were a small number of studies written about the results of thalidomide therapy in non-transplant MM patients.
Aungchaisuksiri Pantep +7 more
doaj +1 more source
Molecular Mechanisms of the Teratogenic Effects of Thalidomide
Pharmaceuticals, 2020 Thalidomide was sold worldwide as a sedative over 60 years ago, but it was quickly withdrawn from the market due to its teratogenic effects. Thalidomide was later found to have therapeutic effects in several diseases, although the molecular mechanisms ...
Tomoko Asatsuma-Okumura +2 more
doaj +1 more source
Lenalidomide reduces microglial activation and behavioral deficits in a transgenic model of Parkinson's disease. [PDF]
, 2015 BackgroundParkinson's disease (PD) is one of the most common causes of dementia and motor deficits in the elderly. PD is characterized by the abnormal accumulation of the synaptic protein alpha-synuclein (α-syn) and degeneration of dopaminergic neurons ...
Anderson, Scott +4 more
core +2 more sources
Intracranial tuberculous mass lesions treated with thalidomide in an immunocompetent child from a low tuberculosis endemic country: A case report [PDF]
, 2018 Rationale: Tuberculous meningitis is a highly morbid, often fatal disease. Patient concern: We describe a case of an Italian child. Diagnoses: we diagnosed early a Tuberculous meningitis complicated by the occurrence of hydrocephalus, stroke, and ...
Ajassa, Camilla +8 more
core +1 more source
Neural Regeneration Research, 2015 Thalidomide is an effective drug for the treatment of ankylosing spondylitis but might induce peripheral neuropathy. This major adverse reaction has attracted much concern.
Hong-xia Xue +5 more
doaj +1 more source